Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PDE9A | O76083 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 7/20 | 0.40 |
| ▸ | RAB9A | P51151 | 7/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19531869 | 0.80 | CYP11B1 (0.48) | CYP11B1CYP11B2EZH2PDE9AHTR2A | |
| SCHEMBL21733234 | 0.80 | ADRA2A (0.41) | EZH2PDE9ANPC1RAB9AKMT2A | |
| SCHEMBL4953281 | 0.80 | EZH2 (0.41) | CYP11B1CYP11B2EZH2PDE9AKMT2A | |
| SCHEMBL29303420 | 0.80 | EZH2 (0.39) | CYP11B1CYP11B2EZH2PDE9ANPC1 | |
| SCHEMBL30975428 | 0.80 | EZH2 (0.39) | CYP11B1CYP11B2EZH2PDE9ANPC1 | |
| SCHEMBL12120875 | 0.80 | EZH2 (0.39) | CYP11B1CYP11B2EZH2PDE9AHTR2C | |
| SCHEMBL20353817 | 0.77 | EZH2 (0.37) | CYP11B1CYP11B2EZH2PDE9A | |
| SCHEMBL19910588 | 0.77 | EZH2 (0.42) | EZH2POLBPDE9A | |
| SCHEMBL15687199 | 0.76 | EZH2 (0.41) | EZH2PDE9ARAB9AKMT2A | |
| SCHEMBL24339586 | 0.75 | NPC1 (0.41) | CYP11B1CYP11B2POLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190192697-A1 | CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF | PHARMAKEA, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192697-A1 | CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF | LOXL2, LOXL1, LOXL3 | CYP11B1 2303/4885CYP11B2 1042/4885EZH2 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.